UBXN11 (UBX Domain Protein 11)

Finally, we identified a potential 3'aSNP rs11583258 associated with the risk of lung cancer both in the GWMA [OR = 1.04 (1.02-1.06), P = 1.00 × 10-4] and in the validation stage [OR = 1.08 (1.01-1.16), P = 1.01 × 10-2] at 1p36.11. Function annotation integrating the results of multiple public datasets suggested the variants in this region might affect both the length of the 3'UTR of the UBXN11 transcripts and the expression of UBXN11 to affect the susceptibility of lung cancer.

We establish an HPV-associated SNSCC cell line, showing that combinatorial small-molecule inhibition of YAP/TAZ and PI3K synergistically suppresses clonogenicity. Combining YAP/TAZ blockade with vertical PI3K inhibition may benefit HPV-associated SNSCC, whereas targeting MYC and horizontal inhibition of RAS/PI3K may suit HPV-independent SNSCC.

This study successfully established and validated a novel 13-gene signature, a valuable marker for predicting cervical cancer patient survival.

Combinatorial blockade of YAP/TAZ and vertical inhibition of the PI3K pathway may be useful in targeting HPV-associated SNSCC whereas targeting MYC and horizontal inhibition of RAS/PI3K pathways for HPV-independent SNSCC. This study solidifies HPV as a driver of HPV-associated SNSCC tumorigenesis, identifies molecular mechanisms distinguishing HPV-associated and HPV-independent SNSCC, and elucidates YAP/TAZ and PI3K blockade as key targets for HPV-associated SNSCC.

This study underscores the pivotal role of UBXN11 in CRC progression and paves the way for novel therapeutic strategies for CRC treatment.

Downregulation of KIF5C, TUBB3 and RAB6B targets is associated with poor prognosis in patients diagnosed with adenocarcinoma. Collectively, this integrative investigation establishes the post-transcriptional mechanisms in the prostate that are modulated by maternal exposure to phthalate mixture during gestation and lactation.

285 AML patients with a median age of 75 were included in the phase 3 PETHEMA-FLUGAZA trial and were randomized to receive induction and consolidation with fludarabine and cytarabine (FLUGA) vs 5-azacitidine (AZA). This study showed that elderly AML patients treated with semi-intensive chemotherapy or hypomethylating agents, have dire survival regardless of achieving PR vs CR/MRD+. However, RNAseq analyses of resistant cells uncovered that whereas PR is characterized by primary resistance and transcriptionally stability from diagnosis, CR/MRD+ is associated with the emergence of molecular traits of acquired resistance. These findings could help explaining why additional treatment with the same schema is unable to overcome the poor prognosis of persistent MRD in elderly AML patients achieving CR/CRi.

With erlotinib, a single-nucleotide polymorphism mutation in UBXN11 was associated with significantly worse DFS (P = .01). To our knowledge, this study is the first to demonstrate clinically meaningful OS improvement with adjuvant erlotinib compared with chemotherapy in R0 stage III EGFR+ non-small-cell lung cancer.

This is the first randomized study of EGFR-TKI to demonstrate a clinically meaningful improvement in OS vs chemotherapy in stage III EGFR+ NSCLC (5-year survival rate 84.8% in E vs 51.1% in NP) . The co-occurring variants at baseline may be associated with reduced DFS . Further studies are required to confirm our results (EVAN, NCT01683175).